Nuvation Bio to Present at the Jones Healthcare and Technology Innovation Conference
Nuvation Bio (NYSE: NUVB), a global biopharmaceutical company focused on oncology, has announced its upcoming participation in the Jones Healthcare and Technology Innovation Conference.
The company's leadership, including Founder, President, and CEO David Hung, M.D., and CFO Philippe Sauvage, will engage in a fireside chat scheduled for April 9, 2025, at 10:00 a.m. PT/1:00 p.m. ET in Las Vegas.
An audio recording of the presentation will be accessible on the company's investor relations website at investors.nuvationbio.com/investors/ and will remain available for 90 days after the event.
Nuvation Bio (NYSE: NUVB), un'azienda biopharmaceutica globale focalizzata sull'oncologia, ha annunciato la sua prossima partecipazione alla Jones Healthcare and Technology Innovation Conference.
La leadership dell'azienda, inclusi il Fondatore, Presidente e CEO David Hung, M.D., e il CFO Philippe Sauvage, parteciperà a una chiacchierata informale programmata per il 9 aprile 2025, alle 10:00 PT/13:00 ET a Las Vegas.
Una registrazione audio della presentazione sarà disponibile sul sito web delle relazioni con gli investitori dell'azienda all'indirizzo investors.nuvationbio.com/investors/ e rimarrà accessibile per 90 giorni dopo l'evento.
Nuvation Bio (NYSE: NUVB), una compañía biofarmacéutica global centrada en oncología, ha anunciado su próxima participación en la Jones Healthcare and Technology Innovation Conference.
El liderazgo de la compañía, incluyendo al Fundador, Presidente y CEO David Hung, M.D., y al CFO Philippe Sauvage, participará en una charla informal programada para el 9 de abril de 2025, a las 10:00 a.m. PT/1:00 p.m. ET en Las Vegas.
Una grabación de audio de la presentación estará disponible en el sitio web de relaciones con inversores de la compañía en investors.nuvationbio.com/investors/ y permanecerá accesible durante 90 días después del evento.
누베이션 바이오 (NYSE: NUVB)는 종양학에 중점을 둔 글로벌 생물 제약 회사로, 존스 헬스케어 및 기술 혁신 컨퍼런스에 참여할 예정이라고 발표했습니다.
회사의 리더십, 즉 설립자이자 CEO인 David Hung, M.D.와 CFO Philippe Sauvage가 2025년 4월 9일 오전 10:00 PT/오후 1:00 ET에 라스베이거스에서 예정된 대화에 참여할 것입니다.
프레젠테이션의 오디오 녹음은 회사의 투자자 관계 웹사이트인 investors.nuvationbio.com/investors/에서 확인할 수 있으며, 이벤트 후 90일 동안 이용 가능합니다.
Nuvation Bio (NYSE: NUVB), une entreprise biopharmaceutique mondiale axée sur l'oncologie, a annoncé sa prochaine participation à la Jones Healthcare and Technology Innovation Conference.
La direction de l'entreprise, y compris le Fondateur, Président et CEO David Hung, M.D., et le CFO Philippe Sauvage, participera à une discussion informelle prévue pour le 9 avril 2025, à 10h00 PT/13h00 ET à Las Vegas.
Un enregistrement audio de la présentation sera accessible sur le site web des relations avec les investisseurs de l'entreprise à l'adresse investors.nuvationbio.com/investors/ et restera disponible pendant 90 jours après l'événement.
Nuvation Bio (NYSE: NUVB), ein globales biopharmazeutisches Unternehmen, das sich auf Onkologie spezialisiert hat, hat seine bevorstehende Teilnahme an der Jones Healthcare and Technology Innovation Conference angekündigt.
Die Unternehmensführung, darunter Gründer, Präsident und CEO David Hung, M.D. sowie CFO Philippe Sauvage, wird an einem informellen Gespräch teilnehmen, das für den 9. April 2025 um 10:00 Uhr PT/13:00 Uhr ET in Las Vegas geplant ist.
Eine Audioaufnahme der Präsentation wird auf der Website für Investorenbeziehungen des Unternehmens unter investors.nuvationbio.com/investors/ verfügbar sein und bleibt 90 Tage nach der Veranstaltung zugänglich.
- None.
- None.
An audio replay of the fireside chat will be available following the event on the Nuvation Bio website at https://investors.nuvationbio.com/investors/. An archived recording will be available for 90 days following the event.
About Nuvation Bio
Nuvation Bio is a global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel product candidates. Nuvation Bio’s programs include taletrectinib (ROS1), safusidenib (mIDH1), NUV-1511 (DDC), and NUV-868 (BET). Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250402120689/en/
Nuvation Bio Investor Contact:
ir@nuvationbio.com
Nuvation Bio Media Contact:
media@nuvationbio.com
Source: Nuvation Bio Inc.
FAQ
When and where will Nuvation Bio (NUVB) present at the Jones Healthcare Conference 2025?
Who will represent NUVB at the Jones Healthcare Conference 2025?
How can investors access NUVB's Jones Healthcare Conference presentation?
What is Nuvation Bio's (NUVB) primary business focus?
